Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

79.25USD
4:02pm EDT
Change (% chg)

$-1.97 (-2.43%)
Prev Close
$81.22
Open
$80.53
Day's High
$80.67
Day's Low
$79.12
Volume
357,456
Avg. Vol
309,580
52-wk High
$95.11
52-wk Low
$70.00

NVS.N

Chart for NVS.N

About

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $212,588.70
Shares Outstanding(Mil.): 2,627.11
Dividend: 2.72
Yield (%): 3.35

Financials

  NVS.N Industry Sector
P/E (TTM): 29.37 37.70 37.57
EPS (TTM): 2.77 -- --
ROI: 6.33 14.41 13.91
ROE: 8.82 15.24 14.85

Amgen, Arrowhead team up on gene-therapies for heart disease

Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

10:15am EDT

UPDATE 1-Amgen, Arrowhead team up on gene-therapies for heart disease

Sept 29 Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

9:56am EDT

After CEO move, GSK picks ex-Novartis exec to head consumer unit

LONDON GlaxoSmithKline has promoted a former Novartis executive to lead its consumer healthcare business, following the appointment last week of the unit's previous head, Emma Walmsley, as CEO designate of the drugmaker.

8:25am EDT

After CEO move, GSK picks ex-Novartis exec to head consumer unit

LONDON, Sept 29 GlaxoSmithKline has promoted a former Novartis executive to lead its consumer healthcare business, following the appointment last week of the unit's previous head, Emma Walmsley, as CEO designate of the drugmaker.

8:20am EDT

Swiss stocks - Factors to watch on Sept. 29

ZURICH, Sept 29 The Swiss blue-chip SMI was seen opening 0.6 percent higher at 8,273 points on Thursday, according to premarket indications by bank Julius Baer .

2:07am EDT

BRIEF-Novartis says receives three new FDA approvals for expanded use of Ilaris treating rare periodic fever syndrome conditions

* Says receives three new approvals from the U.S. Food and Drug Administration for expanded use of Ilaris treating rare periodic fever syndrome conditions.

Sep 23 2016

CORRECTED-UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure

ZURICH, Sept 23 Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug.

Sep 23 2016

Novartis's Zykadia gets positive results, faces Roche pressure

ZURICH Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug.

Sep 23 2016

Novartis drug Zykadia gets positive trial results

ZURICH, Sept 23 Novartis cancer drug Zykadia showed positive results in a phase III clinical trial in treating patients with a form of lung cancer, the Swiss drugmaker said on Friday.

Sep 23 2016

Divided U.S. Supreme Court turns to less sensitive IP cases

WASHINGTON Shorthanded and ideologically divided, the U.S. Supreme Court has yet to take up any cases on politically sensitive social issues in its new term starting in October, instead showing a keen interest in more technical cases of importance to business such as disputes over intellectual property.

Sep 21 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $117.27 -2.12
Pfizer Inc. (PFE.N) $33.32 -0.67
Merck & Co., Inc. (MRK.N) $61.91 -1.39
Roche Holding Ltd. (ROG.S) CHF241.80 -2.80
Roche Holding Ltd. (RO.S) CHF242.90 -2.00
Abbott Laboratories (ABT.N) $41.44 -0.85
Sanofi SA (SASY.PA) €68.03 -0.29
AstraZeneca plc (AZN.L) 5,026.00p -96.00
GlaxoSmithKline plc (GSK.L) 1,647.50p -7.50
Eli Lilly and Co (LLY.N) $79.74 -0.97

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.